Nordic Bioscience on Thursday announced the strengthening of an ongoing collaboration with Roche Diagnostics for the development of proprietary biomarkers involved in tissue breakdown and build-up.
According to Nordic, the extracellular matrix markers it develops are essential for chronic diseases involving tissue fibrosis and inflammation, and the collaboration with Roche will facilitate better clinical decisions in drug development and patient selection for precision medicine.
Under the collaboration, Nordic will transfer blood-based biomarkers to Roche to be implemented on Roche's automated Cobas platform.
The Herlev, Denmark-based firm added that, to date, two biomarkers have been commercialized and implemented on the platform. One of the two, fibrogenesis biomarker PRO-C3, is a noninvasive biomarker that quantifies type III collagen formation, which is highly relevant for nonalcoholic steatohepatitis (NASH) and other fibrotic diseases, the firm said.
